Amaryl, Glimepiride News

An experimental diabetes drug called liraglutide appears to outperform exenatide , the only currently approved drug in its class, a study funded by liraglutide's maker, Novo Nordisk, shows.

Novo Nordisk A/S's experimental diabetes drug liraglutide was significantly better at helping patients control blood sugar than an older common medicine after two years of treatment, according to data from a clinical trial.

Novo Nordisk data presented today at the 69th Annual Scientific Sessions of the American Diabetes Association showed that once-daily liraglutide, taken as monotherapy, leads to statistically significant and sustained reductions in blood sugar and weight after two years of treatment.

Links not loading properly? Some of our pages use Portable Document Format files, which require Adobe Acrobat Reader.

Covered by Medicare -- and charged a higher price When Sanford Morris of Minneapolis had to pay out of pocket for three generic drugs, Walgreens charged him nearly $200. He noticed that the drugs sell for a fraction of that price in the pharmacy's Prescription Savings Club.

Data presented at the Diabetes UK Annual Professional Congress in Glasgow show that the, human GLP-1 analogue, liraglutide is effective at reducing HbA1c in patients with type 2 diabetes and also significantly ...

Poor control of type 2 diabetes results in substantial long-term consequences. Studies of new diabetes treatments are rarely designed to assess mortality, complication rates and costs.

In patients with type 2 diabetes being treated with metformin, the addition of the glucagon-like peptide-1 analog liraglutide is as effective as glimepiride in improving glycemic control but with less weight ...